InspireMD cuts chief commercial officer role
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
InspireMD, Inc. reported a leadership change in its commercial organization. On July 23, 2026, the company notified Chief Commercial Officer Shane Gleason that his position has been eliminated. His last day of employment will be July 31, 2026. The update does not describe any successor or structural changes beyond the elimination of this role.
Positive
- None.
Negative
- The position of Chief Commercial Officer held by Shane Gleason has been eliminated, with his last day of employment on July 31, 2026.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Notice date: July 23, 2026
Last day of employment: July 31, 2026
Par value of common stock: $0.0001 per share
3 metrics
Notice date
July 23, 2026
Date InspireMD notified Chief Commercial Officer Shane Gleason his position was eliminated
Last day of employment
July 31, 2026
Final employment date for Chief Commercial Officer Shane Gleason
Par value of common stock
$0.0001 per share
Par value of InspireMD common stock listed on The Nasdaq Capital Market
Key Terms
Chief Commercial Officer, Emerging growth company, Inline XBRL
3 terms
Chief Commercial Officer financial
"the Company’s Chief Commercial Officer, that his position has been eliminated"
A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.
Emerging growth company regulatory
"Emerging growth company Item 5.02. Departure of Directors"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What major event did InspireMD (NSPR) disclose on July 23, 2026?
InspireMD disclosed that it notified Chief Commercial Officer Shane Gleason his position has been eliminated. His employment will end on July 31, 2026, reflecting a change in the company’s commercial leadership structure.
Which executive is leaving InspireMD (NSPR) and what was his role?
The departing executive is Shane Gleason, who serves as InspireMD’s Chief Commercial Officer. The company has notified him that his position has been eliminated, and his employment will conclude at the end of July 2026.
When is Chief Commercial Officer Shane Gleason’s last day at InspireMD (NSPR)?
His last day of employment at InspireMD will be July 31, 2026. The company provided notice on July 23, 2026 that his position as Chief Commercial Officer has been eliminated.
Did InspireMD (NSPR) say why the Chief Commercial Officer role was eliminated?
The company stated only that the position has been eliminated and that Shane Gleason’s last day will be July 31, 2026. No specific reasons or broader restructuring details were described in the disclosure.
Does InspireMD (NSPR) name a replacement for the Chief Commercial Officer?
No replacement was identified. InspireMD stated that the Chief Commercial Officer position itself has been eliminated, and did not describe any successor or new role being created in its place.
AI-generated analysis. How Rhea-AI works. Not financial advice.
